Novo real-world data link Wegovy 2.4mg to lower liver enzymes and weight in people with MASH
_Image credit: Novo Nordisk via PR Newswire_
At the AASLD Liver Meeting, Novo presented two retrospective US studies in adults with the fatty liver disease MASH. In one, semaglutide 2.4mg users lost about 8.6kg at six months versus about 2.5kg on resmetirom, with a bigger drop in the liver enzyme AST; in the other, starters lost about 30.7lb over a year versus 2.4lb in non-users. Novo notes the studies were observational, so they show associations rather than proof of cause.
Source: Novo Nordisk via PR Newswire (6 Nov 2026). Image: Novo Nordisk via PR Newswire.